The DiaCoVAb Study in South Italy: Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients.
Booster
Dialysis
Severe acute respiratory syndrome coronavirus 2
Vaccination
Journal
Kidney & blood pressure research
ISSN: 1423-0143
Titre abrégé: Kidney Blood Press Res
Pays: Switzerland
ID NLM: 9610505
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
01
2022
accepted:
08
03
2022
pubmed:
24
3
2022
medline:
7
7
2022
entrez:
23
3
2022
Statut:
ppublish
Résumé
Since the pandemic of COVID-19 started from December 2019, remarkable numbers of infections and deaths associated with COVID-19 have been recorded worldwide. End-stage kidney disease patients on dialysis are particularly at high risk of infections due to impairments in the innate and adaptive immune systems. Vaccination on dialysis patients (DP) still remains challenging because of the variable response and a low seroconversion rate compared with healthy participants (HP). Therefore, it is urgently necessary to establish a different vaccination strategy for DP, in terms of the dose and administration time. Here, we report an observational prospective cohort study in which the immunogenic efficacies of SARS-CoV-2 vaccine BNT162b2 on DP and HP were evaluated by absolute quantification of IgG levels in the blood. DP showed a delayed seroconversion after two vaccine doses, with a low absolute IgG levels compared to HP. While HP reached complete seroconversion within 10 days from the administration of a second dose, only 76% of DP were seropositive. After the booster dose, DP had a strongly improved seroconversion rate as well as antibody levels, reaching 97% seropositivity and 50 times enhancement on antibody levels. These results prompt to suggest an additional vaccine dose in DP, reducing the interval of time from the second dose. Since limited data are available on immune response in DP overtime after three vaccine doses currently, our study is among the first reports demonstrating the improved seropositivity and IgG levels in DP after the booster vaccine dose.
Identifiants
pubmed: 35318291
pii: 000524034
doi: 10.1159/000524034
pmc: PMC9148885
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Viral Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-474Informations de copyright
© 2022 The Author(s). Published by S. Karger AG, Basel.
Références
Lancet. 2015 May 16;385(9981):1975-82
pubmed: 25777665
Int J Nephrol Renovasc Dis. 2020 Jul 27;13:179-185
pubmed: 32801834
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Kidney Int. 2021 Jun;99(6):1496-1498
pubmed: 33887318
Adv Chronic Kidney Dis. 2019 Jan;26(1):72-78
pubmed: 30876620
Kidney Int. 2020 Dec;98(6):1540-1548
pubmed: 32979369
Nat Rev Dis Primers. 2017 Nov 23;3:17088
pubmed: 29168475
Kidney Int. 2021 Jun;99(6):1490-1492
pubmed: 33887317
Kidney Int. 2009 May;75(10):1009-14
pubmed: 19242501
Kidney Int. 2021 Jun;99(6):1492-1494
pubmed: 33887316
Clin J Am Soc Nephrol. 2008 Sep;3(5):1526-33
pubmed: 18701615
Lancet. 2021 Dec 11;398(10317):2126-2128
pubmed: 34871545
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Kidney Int. 2021 Jun;99(6):1494-1496
pubmed: 33887320
Int J Environ Res Public Health. 2019 Mar 04;16(5):
pubmed: 30836681
Lancet Respir Med. 2022 Feb;10(2):e17
pubmed: 34929158
Am J Kidney Dis. 2022 Feb;79(2):185-192.e1
pubmed: 34508833
Lancet. 2020 Feb 29;395(10225):662-664
pubmed: 32061314
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315